NCT00251472已完成2 期
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 2
- 主要终点
- To assess the response rate of Abraxane given weekly as first-line treatment for patients with locally advanced or metastatic breast cancer.
研究概览
简要总结
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.
Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible for the study, patients must fulfill all of the following criteria:
- •Patients must have signed an IRB-approved informed consent.
- •Patients must have histologically or pathologically confirmed and documented locally advanced or metastatic breast cancer. Patients may be Her2+ or Her2-.
- •Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension as >2 cm with conventional techniques or as >1 cm with spiral CT scan. Palpable disease is acceptable.
- •Patients must be >18 years of age.
- •Patients must have an ECOG Performance Status of 0 or 1 (see Appendix I).
- •Patients' estimated life expectancy must be at least 12 weeks.
- •Patients may have received prior adjuvant chemotherapy for breast cancer, including taxane-containing regimens, provided this treatment was completed at least 12 months prior to enrollment.
- •Patients may have received prior radiation (except for radiation to the entire pelvis), provided that less than 25% of the bone marrow has been treated, and the patient has recovered from the acute toxic effects of treatment prior to trial enrollment. Prior radiation treatment must have been completed at least 4 weeks prior to enrollment. Lesions that have been irradiated in the advanced disease setting may not be included as sites of measurable disease.
- •Patients may have received prior hormonal, AI (aromatase inhibitors) therapy, or immunotherapy. All hormonal, AI, and immunotherapy must have been terminated prior to enrollment.
- •Patients must have adequate liver function defined as: for patients with no liver metastases, aspartate transaminase (AST), alanine transaminase (ALT), and bilirubin levels can be up to 1.5 times the upper limit of normal (ULN). For patients with liver metastases, ALT, AST, and bilirubin levels can be up to 2.5 times the ULN.
- •Patients must have adequate renal function defined as: creatinine < 2mg/dL or calculated creatinine clearance must be > 40mL/min.
- •Patients must have adequate bone marrow function, including absolute neutrophil count (ANC) ³1500/µL, platelet count ³100,000/µL, and hemoglobin ³9 g/dL.
- •Patients must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal for at least 12 months.
- •Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter.
- •Patients must be willing and able to comply with scheduled visits, treatment plan and laboratory testing, and be accessible for follow-up.
排除标准
- •Any of the following criteria will make the patient ineligible to participate in this study:
- •Patients who have received prior chemotherapy for the treatment of metastatic breast cancer.
- •Patients who have received prior Abraxane.
- •Patients who have a history of hypersensitivity to taxanes or any of the components in taxanes or Abraxane.
- •Patients with serious intercurrent medical or psychiatric illness.
- •Patients with a second primary malignancy, except carcinoma in situ of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated >5 years previously and with no evidence of recurrence.
- •Patients with only non-measurable disease, defined as all other lesions including small lesions and truly non-measurable lesions.
- •Patients with parenchymal or leptomeningeal brain metastases.
- •Patients planning to receive any concurrent therapy to treat metastatic or locally advanced breast cancer during the study treatment period.
- •Any patient who is pregnant or lactating.
结局指标
主要结局
To assess the response rate of Abraxane given weekly as first-line treatment for patients with locally advanced or metastatic breast cancer.
时间窗: unk
次要结局
- To assess time to progression (TTP), overall survival (OS), and toxicities of Abraxane as first-line treatment for patients with locally advanced or metastatic breast cancer.(unk)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerBreast CancerNCT00607438Veeda Oncology16
已完成
2 期
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II StudyMetastatic Malignant MelanomaNCT00462423Lynn E. Spitler, MD50
已完成
2 期
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerRecurrent Ovarian CarcinomaFallopian Tube CarcinomaPrimary Peritoneal CarcinomaNCT00499252Gynecologic Oncology Group51
已完成
不适用
Phase 2 trial of Abraxane, albumin-bound paclitaxel, in patients with previously treated non-small cell lung cancerPreviously treated non-small cell lung cancerJPRN-UMIN000010841niversity of Fukui Hospital30
已完成
2 期
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerNCT01620190University of Washington26